PATENT CLAIM ANALYSIS

Application Number: 15746214
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "423000"]

Abstract:
Endogenous mechanisms leading to host protection and resolution of infections without immunosuppression are of wide interest. Here we elucidated the structures of four new host-protective molecules produced in neutrophil-endothelial co-cultures, and present in human and mouse tissues after sterile inflammation or infection. These bioactive molecules contained conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and were derived from n-3 docosapentaenoic acid (DPA, C22:5). These compounds, termed 13-series resolvins (RvT), demonstrated potent protective actions increasing mice survival during  Escherichia coli  infections. RvT also regulated human and mouse phagocyte responses stimulating bacterial phagocytosis and regulating inflammasome components. Their biosynthesis during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 (COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. The actions of atorvastatin and RvT were additive in  E. coli  infections in mice where they accelerated resolution of inflammation and increased survival >60%.

Claim (Index 7):
A method to treat or prevent one or more of inflammasome activation, diabetes, nasopharyngitis, arthralgia, diarrhea, pain in the extremities, bacterial infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngia pain, inflammation, arterial inflammation, arthritis, psoriasis, urticara, vasculitis, asthma, ocular inflammation, pulmonary inflammation, pulmonary fibrosis, seborrheic dermatitis, pustular dermatosis, cardiovascular diseases, recruitment of neutrophils, leukocytes and/or cytokines, allergy, Alzheimer's disease, asthma, atherosclerosis, cancer, cardiovascular diseases, diabetes, genitourinary disorders, hypertension, infectious diseases, neuromuscular disorders, renal disorders, oral infections or periodontal disease comprising the step of administering an effective amount of one or more of compounds having the formulae: wherein each of P 1 , P 2  and/or P 3 , when present, individually is a protecting group or a hydrogen atom; , when present, represents a double bond; and wherein each double bond is independently in the Z or the E configuration; Z is \u2014C(O)OR d , \u2014C(O)NR c R c , \u2014C(O)H, \u2014C(NH)NR c R c , \u2014C(S)H, \u2014C(S)OR d , \u2014C(S)NR c R c , or \u2014CN; each R a , is independently selected from hydrogen, (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, (C4-C11) cycloalkylalkyl, (C5-C10) aryl, phenyl, (C6-C16) arylalkyl, benzyl, 2-6 membered heteroalkyl, 3-8 membered cycloheteroalkyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, 4-11 membered cycloheteroalkylalkyl, 5-10 membered heteroaryl or 6-16 membered heteroarylalkyl; each R c , is independently a protecting group or R a , or, alternatively, each R c  is taken together with the nitrogen atom to which it is bonded to form a 5 to 8-membered cycloheteroalkyl or heteroaryl which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different R a  or suitable R b  groups; each R b  is independently selected from \u2550O, \u2014OR d , (C1-C3) haloalkyloxy, \u2014OCF 3 , \u2550S, \u2014SR d , \u2550NR d , \u2550NOR d , \u2014NR c R c , halogen, \u2014CF 3 , \u2014CN, \u2014NC, \u2014OCN, \u2014SCN, \u2014NO, \u2014NO 2 , \u2550N 2 , \u2014N 3 , \u2014S(O)R d , \u2014S(O) 2 R d , \u2014S(O) 2 OR d , \u2014S(O)NR c R c , \u2014S(O) 2 NR c R c , \u2014OS(O)R d , \u2014OS(O) 2 R d , \u2014OS(O) 2 OR d , \u2014OS(O) 2 NR c R c , \u2014C(O)R d , \u2014C(O)OR d , \u2014C(O)NR c R c , \u2014C(NH)NR c R c , \u2014C(NR a )NR c R c R c , \u2014C(NOH)R a , \u2014C(NOH)NR c R c , \u2014OC(O)R d , \u2014OC(O)OR d , \u2014OC(O)NR c R c , \u2014OC(NH)NR c R c , \u2014OC(NR a )NR c R c , \u2014[NHC(O)] n R d , \u2014[NR a C(O)] n R d , \u2014[NHC(O)] n OR d , \u2014[NR a C(O)] n OR d , \u2014[NHC(O)] n NR c R c , \u2014[NR a C(O)] n NR c R c , \u2014[NHC(NH)] n NR c R c  or \u2014[NR a C(NR a )] n NR c R c ; each n, independently is an integer from 0 to 3; and each R d , independently is a protecting group or R a ; or a pharmaceutically acceptable salt thereof, provided when Z is \u2014C(O)OR d , then R d  for Z is not a hydrogen when P 1 , P 2  and P 3  are each hydrogen atoms, to a subject in need thereof, such that the disease or condition is treated or prevented.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 86.0
- Lexical Diversity: 1.45536
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['10639714', '13007600', '11836460', '14064803', '14124761']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8016033988757509
- 35 USC 102 Novelty (BERT): 0.5379678422492722
- Combined Prediction Score: 0.775239843213103
- Mean Citation Score: 380.788864
- Max Citation Score: 393.12112
- Similarity Product: 247.2199739473915

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test